Jingchun Liu Selected Research

Adrenergic Antagonists (Antiadrenergic Agents)

1/2008	(Phenylpiperazinyl)cyclohexylureas: discovery of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
11/2007	Aminocyclohexylsulfonamides: discovery of metabolically stable alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
7/2007	(Phenylpiperidinyl)cyclohexylsulfonamides: development of alpha1a/1d-selective adrenergic receptor antagonists for the treatment of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS).
6/2007	(Arylpiperazinyl)cyclohexylsufonamides: discovery of alpha(1a/1d)-selective adrenergic receptor antagonists for the treatment of Benign Prostatic Hyperplasia/Lower Urinary Tract Symptoms (BPH/LUTS).

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jingchun Liu Research Topics

Disease

5	Prostatic Hyperplasia (Benign Prostatic Hyperplasia) 01/2008 - 03/2007
5	Lower Urinary Tract Symptoms 01/2008 - 03/2007
4	Stroke (Strokes) 01/2022 - 01/2018
3	Neoplasms (Cancer) 01/2021 - 01/2014
3	Prostatic Neoplasms (Prostate Cancer) 05/2017 - 06/2014
2	Inflammation (Inflammations) 01/2021 - 01/2020
2	Transfusion Reaction 11/2018 - 01/2017
2	Urinary Bladder Neoplasms (Bladder Cancer) 01/2014 - 11/2013
1	COVID-19 05/2022
1	Disease Progression 01/2020
1	Infections 10/2019
1	Human Influenza (Influenza) 10/2019
1	Virus Diseases (Viral Diseases) 01/2017
1	Anemia 01/2017
1	Hemolysis 01/2016
1	Renal Insufficiency (Renal Failure) 01/2016
1	Multiple Sclerosis 12/2013
1	Pain (Aches) 03/2005

Drug/Important Bio-Agent (IBA)

4	Biomarkers (Surrogate Marker)IBA 01/2022 - 01/2018
4	Adrenergic Antagonists (Antiadrenergic Agents)IBA 01/2008 - 06/2007
4	alpha-1 Adrenergic Receptors (alpha 1 Adrenergic Receptor)IBA 01/2008 - 03/2007
3	IsoantibodiesIBA 10/2019 - 01/2017
3	AcetogeninsIBA 05/2017 - 06/2014
2	Glycoproteins (Glycoprotein)IBA 01/2020 - 10/2019
1	Anti-Bacterial Agents (Antibiotics)IBA 05/2022
1	Complement System Proteins (Complement)IBA 01/2021
1	Pharmaceutical PreparationsIBA 01/2021
1	AntigensIBA 01/2020
1	Proteins (Proteins, Gene)FDA Link 10/2019
1	chromium hexavalent ionIBA 10/2019
1	Toll-Like Receptor AgonistsIBA 10/2019
1	InterferonsIBA 10/2019
1	Isoantigens (Alloantigen)IBA 01/2016
1	AntibodiesIBA 01/2016
1	SurvivinIBA 01/2014
1	Polylactic Acid-Polyglycolic Acid CopolymerIBA 01/2014
1	Small Interfering RNA (siRNA)IBA 01/2014
1	Polysaccharides (Glycans)IBA 01/2014
1	ChitosanIBA 01/2014
1	teriflunomideIBA 12/2013
1	Dihydroorotate DehydrogenaseIBA 12/2013
1	belinostatIBA 11/2013
1	Histone Deacetylase InhibitorsIBA 11/2013
1	A 17 (A-17)IBA 03/2005
1	Opioid Analgesics (Opioids)IBA 03/2005
1	NociceptinIBA 03/2005
1	Amino Acids FDA Link 03/2005
1	Peptides (Polypeptides)IBA 03/2005

Therapy/Procedure

2	Therapeutics 01/2017 - 11/2013
1	Stroke Rehabilitation 01/2022
1	Biological Therapy 01/2021
1	Drug Therapy (Chemotherapy) 11/2013